microdosing glp-1 receptor agonists for autoimmune conditions: what the research actually shows Users taking glp-1 receptor agonists
Description
Diabetes Res Clin Pract (2006) 73(1):10710
Ltd (China) Structure Therapeutics (US) Viking Therapeutics (US) Amgen Inc
Therapy with GLP-1RA should therefore start with low doses that can be uptitrated ( GLP-1RA has been placed prominently in the international recommendations for the treatment of T2D as the first injectable agent before insulin due to the advantageous outcomes in cardiovascular safety studies that demonstrated a reduction of the combined cardiovascular endpoint three-component major adverse cardiovascular event (MACE-3
Risk of Gastrointestinal bleeding increases with combinations of antithrombotic agents and patient age
Angiotensin-Converting Enzyme 2 and Angiotensin 1-7: Novel Therapeutic Targets
